Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis

References

• Frank S, Durovic S, Kostner G M. The assembly of lipoprotein Lp(a). Eur J Clin Invest 1996; 26: 109–14
   Google Scholar
• Kraft H G, Menzel H, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation: implication for apolipoprotein synthesis. J Clin Invest 1989; 83: 137–42
   PubMed Web of Science ®Google Scholar
• Snyder M L, Hay R V, Whitington P F, Scanu A M, Fless G M. Binding and degradation of lipoprotein(a) and LDL by primary cultures hepatocytes. Comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb 1994; 14: 770–9
   Google Scholar
• Armstrong V W, Harrach B, Robenek H, Helmod M, Walli A K, Seidel D. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J Lipid Res 1990; 31: 429–41
   Google Scholar
• Lackner C, Cohen J, Hobbs H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Molec Genet 1993; 2: 933–40
   PubMed Web of Science ®Google Scholar
• Armstrong V W, Schutz E, Kaltefleiter M, Luy M, Helmhold M, Wieland E, et al. Relationship of apolipoproteins A. I., B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. Eur J Clin Invest 1995; 25: 485–93
   Google Scholar
• Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397–401
   PubMedGoogle Scholar
• Bowden J F, Pritchard P H, Hill J S, Frolich J J. Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1561–8
   PubMedGoogle Scholar
• Heesen B J, Wolffenbuttel B HR, Leurs P B, Sels J PJE, Menheere P PCA, Jackle-Beckers S EC, et al. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993; 23: 580–4
   PubMed Web of Science ®Google Scholar
• Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson B. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296–301
   Google Scholar
• Olivecrona H, Ericsson S, Berglund L, Angelin B. Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment. Br Med J 1993; 306: 1726–7
   PubMed Web of Science ®Google Scholar
• Engler H, Riesen W. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466–9
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Albers J J, Jacobs D R, Perkins L L, Lewis C E, Howard B V, et al. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans. Arterioscler Thromb 1993; 13: 1037–45
   Google Scholar
• Brown S A, Hutchinson R, Morrissett J, et al. Plasma lipid, lipoprotein cholesterol, and apolipoprotein distribution in selected US communities. The Atherosclerosis Risk In Communities (ARIC) Study. Arterioscler Thromb 1993; 13: 1139–58
   PubMedGoogle Scholar
• De Pergola G, Giorgino F, Cospite M, Giagulli V, Cignarelli M, Ferri G, et al. Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women. Arterioscler Thromb 1993; 13: 675–9
   PubMedGoogle Scholar
• Jhaines C, Chung T, Masarei J, Tomlinson B, Lau J. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoprotein. Atherosclerosis 1996; 119: 215–22
   Google Scholar
• Shewmon D, Stock J, Rosen C, Heiniluoma K, Hogue M, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14: 1586–93
   PubMed Web of Science ®Google Scholar
• Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20–3
   PubMed Web of Science ®Google Scholar
• Bostom A G, Cupples A, Jenner J L, Ordovas J M, Seman L J, Wilson P WF, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc 1996; 276: 544–8
   PubMed Web of Science ®Google Scholar
• Brown S, Morissett J, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the ARIC study. Arterioscler Thromb 1993; 13: 1558–66
   PubMedGoogle Scholar
• Cambillau M, Simon A, Amar J, Giral P, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arterioscler Thromb 1992; 12: 1346–52
   PubMedGoogle Scholar
• Lippi G, Ruzzenente O, Facchinetti R, Poli G, Schiesari F, Guidi G C. Latex immunonephelometry for lipoprotein(a) assay. Eur J Lab Med 1994; 2: 23–8
   Google Scholar
• Li K M, Wilcken D EL, Dudman N PB. Effect of serum lipoprotein(a) on estimation of low density lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994; 40: 571–3
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Lippi G, Bagatell C J, Bremner W J. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996; 122: 89–95
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1–13
   PubMed Web of Science ®Google Scholar
• Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol 1985; 110: 11–18
   Google Scholar
• Kopera H. Anabolic-androgen steroid therapy towards the year 2000. Blackwell MZV, Vienna 1993
   Google Scholar
• Anderson R A, Wallace E M, Wu F C. Effect of testosterone enanthate on serum lipoproteins in man. Contraception 1995; 52: 115–19
   PubMed Web of Science ®Google Scholar
• Albers J J, Taggart H M, Applebaum-Bowden D, Haffner S, Chesnut C H, Hazzard W R. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta 1984; 795: 293–6
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Ueyama Y, Nozaki S, et al. Marked hypocholesterolemia in a case with adrenal adenoma-enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J Clin Endocrinol Metab 1995; 80: 92–6
   Google Scholar
• Ebeling P, Koiovisto V A. Physiological importance of dehydroepiandrosterone. Lancet 1994; 343: 1479–81
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Levine D M, Lippi G. Lipoprotein(a): structure, measurement, and clinical significance. Laboratory measurement of lipids, lipoproteins, and apolipoproteins, N Rifai, R Warnick. AACC Press, Washington, DC 1994; 253–64
   Google Scholar
• Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson J. Lipoprotein(a) (Lp(a)) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41–7
   PubMed Web of Science ®Google Scholar